期刊文献+

自发性脑出血患者血清基质金属蛋白酶-9及其抑制因子水平的研究 被引量:1

Investigation of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase in patients with spontaneous intracerebral hemorrhage
原文传递
导出
摘要 目的研究自发性脑出血患者血清基质金属蛋白酶9(MMP9)及其抑制剂水平与脑水肿体积的关系。方法采用酶联免疫吸附法对30例24h内入院的脑出血患者血清MMP9和组织抑制因子1(TIMP1)水平进行测定,与正常对照组进行比较,并对患者进行神经功能评分,根据头部CT扫描所示计算血肿周围水肿(PHE)体积。结果脑出血患者血清MMP9及TIMP1水平较正常对照组明显升高[脑出血组分别为(107.60±49.47)μg/L、(385.99±97.22)μg/L;正常对照组分别为(57.15±40.67)μg/L、(298.27±78.61)μg/L;均为P<0.05],基底节区出血组MMP9的含量与CT所示出血灶周围水肿区体积呈显著正相关(r=0.705,P<0.01)。结论脑出血患者血清MMP9及TIMP1代谢异常,血清MMP9水平可反映脑出血患者血肿周围水肿严重程度,对其含量测定有助于判断病情。 Objective To study the serum levels of matrix metaUoproteinase-9 (MMP-9) and tissue inhibitor of metaUoproteinase (TMP-1) in patients with spontaneous intraeerebral hemorrhage ( ICH ) and the relationship between the level of MMP-9 and the edema volume. Methods MMP-9 and TIMP-1 were determined by enzyme- linked immunosorbent assay in 30 ICH patients who were admitted within 24 h. Neurologie score was measured on admission. Perihematomal edema volumes were measured aeeording to CT sean. Results Serum levels of MMP-9 and TIMP-1 were higher in ICH patients than in normal control [ ( 107.60 ± 49.47 μg/L, ( 385.99 ± 97.22 ) μg/L vs (57.15 ±40.67)μg/L,298.27 ±78.61 μg/L,P 〈 0.05 for each] ,serum levels of MMP-9 in the basal ganglia hemorrhage group were positively correlated with perihematomal edema volume ( r = 0.705 ,P 〈 0.01 ). Conclusion There is the abnormal metabolism of MMP-9 and TIMP-1 in ICH patients. Serum MMP-9 level may refleet the severity of perihematomal edema and is helpful to the judgment of its contents.
出处 《中国综合临床》 北大核心 2006年第6期500-502,共3页 Clinical Medicine of China
基金 河北省自然科学基金资助项目(C2005000748) 河北省卫生厅医学科学研究重点课题计划资助项目(04049)
关键词 脑出血 基质金属蛋白酶-9 组织抑制因子-1 脑水肿 自发性脑出血 Intracerebral hemorrhage Matrix metaUoproteinase-9 Tissue inhibitor-1 Perihematomal edema
  • 相关文献

参考文献7

  • 1Gasche Y,Copin JC,Sugawara T,et al.Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia[J].J cereb Blood Flow Metab,2001,21(12):1 393-1 400.
  • 2Visse R,Nagase H.Matrix metalloproteinases and tissue inhibitiors of metalloproteinases structure,function,and biochemistry[J].Circ Res,2003,92(8):827-839.
  • 3Rosenberg GA,Navratil M.Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat[J].Neurology,1997,48(4):921-926.
  • 4Power C,Henry S,Del Bigio MR,et al.Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases[J].Ann Neurol,2003,53(6):731-742.
  • 5Montaner J,Alvarez-Sabin J,Molina C,et al.Matrix metalloproteinase expression after human cardioembolic stroke:temporal profile and relation to neurological impairment[J].Stroke,2001,32(12):1 759-1 766.
  • 6Planas AM,Sole S,Justicia C,et al.Expression and activation of matix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia[J].Neurobiol Dis,2001,8(5):833-846.
  • 7周冀英,董为伟,贾建平.脑梗死患者外周血中白细胞基质金属蛋白酶9表达的研究[J].实用医学杂志,2004,20(4):371-373. 被引量:6

二级参考文献27

  • 1各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33150
  • 2Ferroni P, Basili S, Martini F, et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation.J Invesfig Meal, 2003, 51(5):295-300.
  • 3Kalela A, Koivu TA, Sisto T, et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Seand J Clin Lab Invest, 2002,62(5):337- 342.
  • 4Matache C, Stefanescu M, Dragomir C, et al. Matrix metalloproteinase9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus.J Autoimmun, 2003, 20(4):323-331.
  • 5Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke, 1998, 29(10) :2189- 2195.
  • 6Yushchenko M, Mader M, Elitok E, et al. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. J Neurol, 2003,250(10):1224- 1228.
  • 7Loftus I, Naylor R, goodall S, et al. Increased matrix metalloproteinase9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke, 2000,31 ( 1 ) : 40 - 47.
  • 8Lichtinghagen R, Huegel O, Seifert T, et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem, 2000, 46(2) : 183 - 192.
  • 9Lichtinghagen R, Seifert T, Kracke A, et al. Expression of matrix metalloproteinaze-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol, 1999,99( 1 ) : 19 - 26.
  • 10Loftus IM, Goodall S, Crowther M, et al. Increased MMP-9 activity in acute carotid plaques: therapeutic avenues to prevent stroke. Ann N Y Acad Sci, 1999, 878:551 -554.

共引文献5

同被引文献29

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部